COST-EFFECTIVENESS OF FINGOLIMOD, TERIFLUNOMIDE, DIMETHYL FUMARATE AND INTRAMUSCULAR INTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

被引：3
|
作者：
Zhang, X. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.351
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND20
引用
收藏
页码：A59 / A60
页数：2
相关论文
共 50 条
  • [1] Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis
    Xinke Zhang
    Joel W. Hay
    Xiaoli Niu
    CNS Drugs, 2015, 29 : 71 - 81
  • [2] Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis
    Zhang, Xinke
    Hay, Joel W.
    Niu, Xiaoli
    CNS DRUGS, 2015, 29 (01) : 71 - 81
  • [3] Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study
    Kalincik, T.
    Spelman, T.
    Jokubaitis, V.
    Horakova, D.
    Havrdova, E.
    Izquierdo, G.
    Prat, A.
    Girard, M.
    Duquette, P.
    Lugaresi, A.
    Grammond, P.
    Alroughani, R.
    Lechner-Scott, J.
    Prevost, J.
    Terzi, M.
    Grand'Maison, F.
    Boz, C.
    Trojano, M.
    Van Wijmeersch, B.
    Pucci, E.
    Granella, F.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    McCombe, P.
    Solaro, C.
    Van Pesch, V.
    Ozakbas, S.
    Slee, M.
    Spitaleri, D.
    Sanchez-Menoyo, J. L.
    Ampapa, R.
    Hodgkinson, S.
    Karabudak, R.
    Vucic, S.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 325 - 327
  • [4] Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis
    Foley, John F.
    Barnes, Christopher J.
    Nair, Kavita V.
    JOURNAL OF MANAGED CARE PHARMACY, 2013, 19 (01): : S16 - S23
  • [5] Effects of statins on intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis
    Rudick, R.
    Pace, A.
    Panzara, M.
    Rani, S.
    Schrock, J.
    Calabresi, F.
    Confavreux, C.
    Galetta, S.
    Lublin, F.
    Radue, E. W.
    Stuart, W.
    Weinstock-Guttman, B.
    Wynn, D.
    MULTIPLE SCLEROSIS, 2007, 13 : S57 - S57
  • [6] Interferon beta-1a in relapsing-remitting multiple sclerosis
    Blumhardt, L
    HOSPITAL MEDICINE, 1999, 60 (03): : 192 - 195
  • [7] Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy
    Mantovani, Lorenzo Giovanni
    Cortesi, Paolo Angelo
    Cardillo, Alessandra
    Santoni, Laura
    Prosperini, Luca
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 13 - 28
  • [8] COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS, BASED ON THE COMBIRX STUDY
    Darba, J.
    Kaskens, L.
    Sanchez-de la Rosa, R.
    VALUE IN HEALTH, 2013, 16 (07) : A623 - A623
  • [9] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Espallardo, O.
    Crespo, C.
    Polanco, C.
    Nieves, D.
    VALUE IN HEALTH, 2009, 12 (07) : A366 - A367
  • [10] COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Puma, E.
    Santoni, L.
    Prosperini, L.
    VALUE IN HEALTH, 2019, 22 : S740 - S741
12345